AstraZeneca reports Voydeya approved in EU as PNH add-on treatment

Voydeya has been approved in the European Union as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria, or PNH, who have residual haemolytic anaemia. Voydeya is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris or Soliris to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant extravascular haemolysis, or EVH, while treated with a C5 inhibitor, AstraZeneca stated.